MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Pramlintide Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Pramlintide (Symlin) is a synthetic analog of the beta-cell hormone amylin, used as an adjunct to mealtime insulin in type 1 and type 2 diabetes. Three proline substitutions on the 37-amino-acid amylin sequence make it soluble and stable while preserving activity at brainstem amylin receptors. It lowers post-meal glucose by slowing gastric emptying, suppressing post-meal glucagon, and increasing satiety, which also yields modest weight loss (PMID 12610038, 21199269). It does not raise insulin secretion, so it is mechanistically distinct from GLP-1 agonists. Type 1 dosing starts at 15 mcg before major meals and titrates in 15 mcg steps to 30-60 mcg; type 2 dosing is 60-120 mcg, always with mealtime insulin reduced by 50% at the start to manage the boxed-warning risk of severe hypoglycemia. The half-life is about 48 minutes, so it is injected subcutaneously before each major meal rather than once daily. Pramlintide is FDA-approved (2005); the reconstitution figures here are educational only.
Reconstitute: Add 5 mL bacteriostatic water → 1 mg/mL concentration.
Typical dose: 15-60 mcg/meal (T1D); 60-120 mcg/meal (T2D)
Easy measuring: At 1 mg/mL, 1 unit = 0.01 mL = 0.0100 mg (10 mcg) on a U-100 insulin syringe.
Storage: Commercial SymlinPen pens and vials: refrigerate unopened at 2-8 C (36-46 F); an in-use pen or reconstituted solution may be kept refrigerated or at room temperature below 25-30 C and discarded after 30 days. Lyophilized research powder: store frozen at -20 C, protected from light and moisture.
Half-life: About 48 minutes terminal; the glucose- and appetite-lowering effect lasts roughly 3 hours, so it is dosed before each meal rather than once daily.
Route: Subcutaneous before each major meal (abdomen or thigh); the commercial product is a ready-to-use 1,000 mcg/mL pen, injected separately from insulin.
Status: FDA-approved (March 2005) for type 1 and type 2 diabetes as a mealtime-insulin adjunct; boxed warning for severe hypoglycemia; not marketed in the EU.
About Pramlintide
Pramlintide is a synthetic amylin analog (amylinomimetic) given before meals to blunt post-prandial glucose spikes alongside insulin in type 1 and type 2 diabetes [1][2]. Unlike most compounds modeled on this site, pramlintide's real-world route already IS subcutaneous: it is sold as the ready-to-use SymlinPen device at a fixed concentration of 1,000 mcg/mL, injected immediately before each major meal. The vial-and-bacteriostatic-water protocol below simply reproduces that exact 1,000 mcg/mL concentration so the Pramlintide dosage maps cleanly onto a U-100 insulin syringe (every 10 mcg = 1 unit).\n\nThis guide models a 5 mg vial reconstituted with 5.0 mL of bacteriostatic water (1,000 mcg/mL): 15 mcg is about 1.5 units, 30 mcg is about 3 units, 60 mcg is about 6 units, and 120 mcg is about 12 units. Type 1 diabetes starts at 15 mcg per meal and titrates in 15 mcg steps toward a 30-60 mcg target; type 2 diabetes starts at 60 mcg and increases to 120 mcg as tolerated [1]. At initiation, mealtime insulin must be cut by 50% to manage the boxed-warning risk of severe hypoglycemia [1].\n\nFrequency: Inject subcutaneously into the abdomen or thigh immediately before each major meal (at least 250 kcal or 30 g carbohydrate), roughly three times daily, as a separate injection from insulin. Pramlintide is FDA-approved; these reconstitution figures are an educational reference, not medical advice.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 5.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner wall of the 5 mg pramlintide vial; do not spray it directly onto the lyophilized powder, and avoid vigorous shaking.
Gently swirl or roll the vial until the solution is completely clear; the result is 1,000 mcg/mL, the same concentration as the commercial SymlinPen, so 1 insulin-syringe unit equals 10 mcg.
Store refrigerated at 2-8 C and use within about 30 days; draw the prescribed units per meal (15 mcg = 1.5 units, 30 mcg = 3 units, 60 mcg = 6 units, 120 mcg = 12 units). A 0.3 mL / 30-unit U-100 syringe with half-unit markings is best for the small starting doses.
Inject subcutaneously into the abdomen or thigh immediately before each major meal, at least two inches from any insulin injection site, and never mixed in the same syringe as insulin (pramlintide is formulated at an acidic pH).
Interactive Pramlintide Syringe Calculator
Currently visualizing the 5 mg vial reconstituted with 5 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 5mg dry powder in 5mL water yields 1.00 mg/mL. To evaluate a 250mcg dose, pull to 25.0 units (25 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Type 1 - start (with 50% mealtime insulin reduction) | 15 mcg | 2 units (0.01 mL) |
| Type 1 - titrate per meal (wait >=3 days) | 30 mcg | 3 units (0.03 mL) |
| Type 1 target / Type 2 start | 60 mcg | 6 units (0.06 mL) |
| Type 2 - maintenance per meal | 120 mcg | 12 units (0.12 mL) |
Administration guidelines: Refer to guidelines | 5 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 5 mg vial.
Peptide Vials (Pramlintide, 5 mg each):
- checkType 1 at 60 mcg/meal (about 1,260 mcg/week): roughly 2-3 vials over 8 weeks, 3-4 over 12 weeks, 4-5 over 16 weeks
- checkType 2 at 120 mcg/meal (about 2,520 mcg/week) roughly doubles this: about 4 vials (8 weeks), 6 (12 weeks), 8 (16 weeks)
- checkEach 5 mg vial yields 5,000 mcg; once reconstituted, discard after about 30 days even if peptide remains
Insulin Syringes (U-100):
- checkOne syringe per pre-meal injection, about 3 per day = 21 per week
- check8 weeks is about 168 syringes; 12 weeks about 252; 16 weeks about 336
- checkChoose 0.3 mL (30-unit) syringes with half-unit gradations for the small 15 mcg (1.5-unit) starting dose
Bacteriostatic Water (30 mL bottles): Use 5 mL per vial for reconstitution.
- checkType 1: 8 weeks is about 10-15 mL, 12 weeks about 15-20 mL, 16 weeks about 20-25 mL - roughly 1 bottle
- checkType 2: roughly double the volume (about 20-40 mL), or about 1-2 bottles
- checkReconstitute only the vial in use; keep the acidic solution refrigerated and discard after about 30 days
Alcohol Swabs: clean the vial stopper and each injection site.
- checkAbout 2 swabs per injection (vial top plus skin) times 21 injections/week is about 42 per week
- check8 weeks is about 336 swabs; 12 weeks about 504; 16 weeks about 672
- checkBuy in boxes of 100-200; rotate abdomen and thigh sites and keep at least 2 inches from any insulin injection site
Mechanism of Action (MOA)
Pramlintide is a synthetic 37-amino-acid peptide analog of human amylin (also called islet amyloid polypeptide, IAPP), the hormone that pancreatic beta-cells co-secrete with insulin in roughly a 1:100 molar ratio. Because beta-cell loss or dysfunction depletes insulin and amylin together, people with diabetes are amylin-deficient as well as insulin-deficient. Native human amylin cannot be used as a drug because it is highly amyloidogenic and adheres to surfaces; pramlintide replaces three residues (alanine-25, serine-28 and serine-29) with proline, borrowing the non-aggregating sequence found in rodent amylin. These three substitutions keep the peptide soluble and stable while preserving full receptor activity [1][2].\n\nPramlintide is a selective agonist at the amylin receptors (AMY1-3), which are calcitonin-receptor cores complexed with receptor-activity-modifying proteins, concentrated in the area postrema of the hindbrain. Through these receptors it produces three glucose-lowering actions that are independent of insulin: it slows gastric emptying so nutrients reach the small intestine more gradually; it suppresses the inappropriately high postprandial secretion of glucagon that drives hepatic glucose output in diabetes; and it acts centrally to enhance satiety and reduce food intake [1][9]. Crucially, pramlintide does not stimulate insulin secretion, which distinguishes it mechanistically from GLP-1 receptor agonists and from sulfonylureas; it complements rather than replaces mealtime insulin, and the two are given as separate injections [1].\n\nPharmacokinetics: after subcutaneous injection the absolute bioavailability is approximately 30-40%, peak plasma concentration is reached in about 20 minutes, and the terminal half-life is roughly 48 minutes; the glucose- and appetite-modulating effect lasts about three hours, which is why dosing is tied to each major meal rather than given once daily [1][2]. Pramlintide is about 40% plasma-protein bound and is cleared primarily by the kidneys; its principal metabolite, des-lys1-pramlintide (residues 2-37), retains biological activity and a comparable half-life [2]. No dose adjustment is required for mild-to-moderate renal impairment, but it has not been studied in dialysis.\n\nIn clinical use pramlintide is supplied as a ready-to-use 1,000 mcg/mL solution in the SymlinPen 60 (type 1) and SymlinPen 120 (type 2) pen-injectors and is dosed in fixed increments: 15, 30, 45 or 60 mcg per meal for type 1 diabetes and 60 or 120 mcg per meal for type 2 diabetes, titrating only after at least three nausea-free days and after a mandatory 50% cut in mealtime insulin [1]. The subcutaneous vial-reconstitution scheme on this page reproduces that exact 1,000 mcg/mL concentration purely as an educational measurement reference; it is not a substitute for the labeled device or for individualized medical supervision.
Clinical Trial Efficacy Highlights
- starWhitehouse and colleagues (2002, Diabetes Care) ran a 52-week randomized trial in patients with type 1 diabetes; adding pramlintide (30 or 60 mcg before meals) to insulin produced significantly greater reductions in HbA1c and body weight than insulin plus placebo, with transient nausea as the main adverse event [3].
- starRatner and colleagues (2004, Diabetic Medicine) studied 651 patients with type 1 diabetes over one year; pramlintide 60 mcg three or four times daily lowered HbA1c by roughly 0.3% more than placebo and shifted body weight by about 2.4 kg in pramlintide's favor (approximately 1.2 kg loss versus a 1.2 kg gain on placebo), while mealtime insulin requirements fell [4].
- starEdelman and colleagues (2006, Diabetes Care) tested pramlintide against placebo in 296 type 1 patients already on intensive insulin therapy; HbA1c fell similarly in both arms, but the pramlintide group achieved significant weight loss (about 1.3 kg versus placebo) and reduced total insulin use, illustrating that its benefit in optimized regimens is weight- and insulin-sparing rather than large additional A1c lowering [5].
- starHollander and colleagues (2003, Diabetes Care) conducted a 52-week type 2 diabetes randomized controlled trial; pramlintide 120 mcg twice daily produced sustained HbA1c reductions of about 0.62-0.68% versus placebo and a mean weight loss of roughly 1.4 kg, compared with a 0.7 kg gain on placebo [6].
- starA pooled analysis by Hollander and colleagues (2004, Obesity Research) in overweight and insulin-treated type 2 patients found progressive, dose-related weight loss with pramlintide, with the greatest reductions in the most obese subgroups [7].
- starA systematic review and meta-analysis by Singh-Franco and colleagues (2011, Diabetes, Obesity and Metabolism) reported that pramlintide reduced HbA1c by about 0.33% and body weight by about 2.57 kg versus control in type 2 diabetes, with weight reduction also seen in obese patients without diabetes [8].
- starAn independent systematic review by Lee, Norris and colleagues (2010, Annals of Family Medicine) concluded that pramlintide lowers HbA1c modestly (about 0.2-0.3% in type 1 on conventional insulin, about 0.4% in type 2, and with no significant A1c benefit in intensively treated type 1) and consistently reduces weight by roughly 1.5-2.5 kg in type 2, while nausea (about 48-59%) was the dominant harm [9].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningNausea is by far the most common adverse effect, reported in roughly 28-59% of users depending on diabetes type and titration speed; it is usually mild-to-moderate and transient, and is minimized by starting at 15 mcg, waiting at least three days between dose increases, and dosing before food [1][9].
- warningBOXED WARNING - severe hypoglycemia: pramlintide alone does not cause hypoglycemia, but when added to insulin it markedly raises the risk of severe (insulin-induced) hypoglycemia, typically within three hours of injection, especially in type 1 diabetes; mealtime insulin must be reduced by 50% at initiation and re-titrated with frequent glucose monitoring [1].
- warningOther gastrointestinal effects include decreased appetite, vomiting, early satiety and abdominal discomfort, reflecting the drug's slowing of gastric emptying [1][9].
- warningInjection-site reactions, headache, fatigue and dizziness can occur; the solution is acidic (about pH 4) and should reach room temperature before injection to reduce site irritation [1].
- warningContraindications include confirmed hypoglycemia unawareness, gastroparesis or other significant gastric-motility disorders, and known hypersensitivity to pramlintide or metacresol; it is also not recommended for patients with HbA1c above 9%, poor adherence to insulin or glucose monitoring, or recurrent severe hypoglycemia in the prior six months [1].
- warningDrug interactions: because it delays gastric emptying, pramlintide can slow absorption of co-ingested oral drugs - agents needing rapid onset (such as analgesics) should be taken at least 1 hour before or 2 hours after; it must never be mixed in the same syringe as insulin and must be injected at a separate site at least two inches away; caution is warranted with other glucose-lowering or gastrointestinal-motility-altering drugs [1].
- warningPramlintide has not been adequately studied in pregnancy, in children, or in severe renal or hepatic impairment or dialysis, so use in these groups is not established [1].
- warningRegulatory and research status: pramlintide is FDA-approved (2005) and available in the United States only via the prescription SymlinPen; it is not marketed in the EU. The vial-reconstitution and unit figures on this page are an educational modeling reference and do not replace the labeled device, a prescription, or medical supervision [1].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Pramlintide dosage?expand_more
For type 1 diabetes, pramlintide is started at 15 mcg subcutaneously before each major meal and titrated in 15 mcg increments (to 30, 45, then 60 mcg) as nausea allows; the usual target is 30-60 mcg per meal. For type 2 diabetes it is started at 60 mcg and increased to 120 mcg per meal as tolerated. In every case it is given before meals as an adjunct to insulin, and mealtime insulin is cut by 50% when pramlintide is first added [1].
Is Pramlintide FDA approved?expand_more
Yes. The FDA approved pramlintide (Symlin) in March 2005 as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes who have not achieved adequate glucose control. It carries a boxed warning for insulin-associated severe hypoglycemia. It is sold in the United States only and is not marketed in the European Union [1].
How do you reconstitute Pramlintide, and how is it normally supplied?expand_more
Clinically, pramlintide is not reconstituted at all - it is supplied ready-to-use as a 1,000 mcg/mL solution in the SymlinPen 60 and SymlinPen 120 pens. For the educational model here, drawing 5.0 mL of bacteriostatic water into a 5 mg vial reproduces that same 1,000 mcg/mL concentration, so 1 unit on a U-100 syringe equals 10 mcg (15 mcg = 1.5 units, 60 mcg = 6 units, 120 mcg = 12 units). Keep the solution refrigerated and discard after about 30 days [1].
What is Pramlintide's half life and how often is it dosed?expand_more
Pramlintide has a terminal half-life of about 48 minutes, with a peak around 20 minutes after a subcutaneous dose and a glucose- and appetite-modulating effect lasting roughly three hours. Because the effect is short, it is dosed before each major meal (about three times a day) rather than once daily [1][2].
How is Pramlintide different from GLP-1 agonists, and can it be stacked with them?expand_more
Pramlintide is an amylin analog, not an incretin: it works through brainstem amylin receptors to slow gastric emptying, suppress glucagon and increase satiety, and it does not stimulate insulin secretion, which is the opposite of how GLP-1 receptor agonists primarily act. The two pathways are complementary, and combination amylin/GLP-1 research (and newer dual molecules) is active, but pramlintide's FDA label only covers use alongside mealtime insulin, not stacking with GLP-1 agonists [1].
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Pramlintide, plus the universal dosing calculator.
Academic References & Study Citations
U.S. Food and Drug Administration. SYMLIN (pramlintide acetate) injection, for subcutaneous use - Highlights of Prescribing Information (boxed warning, dosing, pharmacokinetics). Revised 02/2015. View Scientific Paper →
McQueen J. Pramlintide acetate. Am J Health Syst Pharm. 2005;62(22):2363-2372. View Scientific Paper →
Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25(4):724-730. View Scientific Paper →
Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21(11):1204-1212. View Scientific Paper →
Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006;29(10):2189-2195. View Scientific Paper →
Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26(3):784-790. View Scientific Paper →
Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004;12(4):661-668. View Scientific Paper →
Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2011;13(2):169-180. View Scientific Paper →
Lee NJ, Norris SL, Thakurta S. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus. Ann Fam Med. 2010;8(6):542-549. View Scientific Paper →